This site is intended for US healthcare professionals

Congresses

The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

American College of Neuropsychopharmacology
December 3rd – 6th 2023, Tampa, FL
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted.
Schizophrenia
ENCORE POSTER
Aripiprazole Lauroxil 2-Month Formulation for Acute Schizophrenia: A Post Hoc Analysis of PANSS Factor Scores in the ALPINE Study
AUTHOR(S)

Leslie Citrome,1 James A. McGrory,2 Martin Dunbar2

Bipolar Disorder
Schizophrenia
ENCORE POSTER
Olanzapine/Samidorphan Effects on Weight Gain: A Meta-analysis of Phase 2 and 3 Randomized, Double-Blind Studies
AUTHOR(S)

Christoph Correll,1-3 Michael J. Doane,4 David McDonnell,5 Sarah Akerman,4 Stephen R. Saklad6